Travere Therapeutics

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Travere Therapeutics reports robust earnings, eyes market expansion opportunities

Travere Therapeutics is on a solid financial footing with promising drug launches and clinical advancements. While facing regulatory and competitive challenges, the company's strategic focus on market expansion and product utilization presents significant growth opportunities. With a strong cash position and ongoing clinical developments, Travere is well-positioned for future success.

Travere Therapeutics reports strong Q1 performance amidst FILSPARI launch

Travere Therapeutics' Q1 performance was driven by strong FILSPARI sales and positive physician adoption.
Despite challenges in FSGS and HCU programs, regulatory flexibility and patient community evolution present opportunities.
Physician interest in FILSPARI data and payer coverage quality are key strengths for the successful launch.
Monitoring metrics and upcoming study readouts offer avenues for growth and optimization in rare disease treatments.

Travere Therapeutics reports strong Q2 performance and growth opportunities

Travere Therapeutics showcased strong performance with revenue growth and positive clinical results across key programs.
The company's strategic focus on core pipeline programs and divestment of non-core assets has bolstered its financial position.
Challenges include competitive dynamics, regulatory uncertainties, and the need for disciplined spending amidst growth opportunities.
Overall, Travere is well-positioned for future growth with promising pipeline programs and a focus on market expansion.

Travere Therapeutics reports strong Q3 performance and strategic advancements

Travere Therapeutics showcased strong operational and financial performance in Q3 2023, with advancements in key programs and positive regulatory engagements.
The company's strategic focus on rare disease treatments, patient education efforts, and regulatory alignment position it well for future growth.
Challenges in revenue forecasting, market positioning, and evolving treatment landscapes highlight areas for ongoing strategic focus and adaptation.
Opportunities in market expansion, revenue growth, program advancements, and patient engagement present avenues for continued success and impact.

Travere Therapeutics reports strong revenue growth and strategic advancements

Travere Therapeutics had a successful year with strong revenue growth and progress in key treatments
Filspari's performance in IgAN drove demand and revenue, positioning the company for further growth
Challenges include the DUPLEX study results and low innovation in the prescriber base
Opportunities lie in sNDA submissions, ongoing studies, and potential for full approval and broader label

Travere Therapeutics excels in Q1 with FILSPARI market success

Travere Therapeutics showcased strong performance and financial stability in Q1 2024, driven by FILSPARI's successful commercial launch and positive patient outcomes.
The company's focus on market adoption, regulatory milestones, and engagement strategies positions it for continued growth and potential inclusion in treatment guidelines.
Challenges in inventory management, regulatory compliance, and strategic alignment with stakeholders need to be addressed to capitalize on growth opportunities and maintain market leadership.

Travere Therapeutics excels in Q2 2024, poised for growth

Travere Therapeutics delivered a strong performance in Q2 2024, driven by FILSPARI's growth and positive regulatory developments.
While facing challenges in regulatory processes and market expansion, the company's solid financial position and ongoing initiatives position it well for future success.
Opportunities for growth abound through potential approvals, global expansion, and advancements in drug development programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Travere Therapeutics stock popped Wednesday after a group of experts suggested an alternative means of measuring the success of FSGS drugs.

Travere Therapeutics Hits 14-Month High On A Promising FDA 'Pivot' In Kidney Disease

NEW YORK CITY, NY / ACCESSWIRE / October 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.

Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESSWIRE / October 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).

Travere Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Travere Therapeutics, Inc. (TVTX)

NEW YORK CITY, NY / ACCESSWIRE / October 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Shareholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESSWIRE / October 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).

Levi & Korsinsky Announces an Investigation on Behalf of Travere Therapeutics, Inc. (TVTX) Shareholders Who May Have Been Affected by Fraud

NEW YORK CITY, NY / ACCESSWIRE / October 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Connect

NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).

Travere Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - TVTX

Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Travere (TVTX) Surges 11.6%: Is This an Indication of Further Gains?

NEW YORK, NY / ACCESSWIRE / October 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).

Investors Who Lost Money on Travere Therapeutics, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - TVTX

NEW YORK CITY, NY / ACCESSWIRE / October 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Investors to Inquire about Securities Investigation

NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).

ATTENTION Travere Therapeutics, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

Travere Therapeutics specializes in rare kidney and metabolic disease treatments with key drugs Filspari and Thiola. Filspari, a key asset for IgA Nephropathy, has received full FDA approval, and its market potential is significant if indications expand. Travere faces risks from supply constraints and paused Pegtibatinase trial, but these are seen as temporary headwinds rather than long-term issues.

Travere Therapeutics Faces Challenges But Holds Promise With Filspari Beyond IgAN

SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).

Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

Travere (TVTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Travere (TVTX) Soars 5.9%: Is Further Upside Left in the Stock?

SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on September 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 33,500 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present at the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 9:45 a.m. ET.

Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference

The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and congenital disabilities.

Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug

Travere Therapeutics stock surged Friday after the biotech company snagged full FDA approval for its kidney disease treatment, Filspari.

Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease

Ligand Pharmaceuticals

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received full approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression. Ligand is entitled to milestone payments and a 9% royalty on worldwide net sales of FILSPARI. FILSPARI was granted accelerated approval in.

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on proteinuria and kidney function preservation that accrued over two years Conversion to full approval based on results from the PROTECT Study, where FILSPARI delivered superior long-term kidney function preservation compared to the active comparator irbesartan in the only Phase 3 head-to-head trial conducted in IgAN As an oral, non-immunosuppressive and dual acting, once-daily medicine with superior long-term results vs. irbesartan, FILSPARI has the potential to become foundational care in IgAN Company to host conference call September 5, 2024, at 6 p.m.

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

Travere Therapeutics' stock has been volatile due to Filspari's failed Phase 3 trials, but a full FDA approval is possible next week that could boost its share price. Despite setbacks, Filspari's unique dual-pathway mechanism and promising clinical data make FDA denial unlikely, supporting a bullish outlook. Travere's financial health is precarious, with significant losses and a potential need for additional funding, but a buyout could be a favorable outcome.

Travere Therapeutics: Judgement Day Is Nigh For Sparsentan

SAN DIEGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present two posters in classical homocystinuria (HCU) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) annual symposium in Porto, Portugal, September 3-6, 2024. At SSIEM, the Company will present the trial designs of the pivotal Phase 3 HARMONY Study and ENSEMBLE long-term extension study of pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of classical HCU.

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Nivi Nehra - Vice President of Corporate Communications and Investor Relations Eric Dube - President and CEO Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - CFO Bill Rote - Senior Vice President of Research & Development Conference Call Participants Tyler Van Buren - TD Cowen Anupam Rama - JPMorgan Joseph Schwartz - Leerink Partners Carter Gould - Barclays Pavan Patel - Bank of America Maurice Raycroft - Jefferies Alex Thompson - Stifel Vamil Divan - Guggenheim Securities Thomas Yip - H.C. Wainwright Operator Good day, and welcome to the Travere Therapeutics' Second Quarter 2024 Financial Results and Corporate Update Conference Call.

Travere Therapeutics, Inc. (TVTX) Q2 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.90 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $1.13 per share a year ago.

News for Travere Therapeutics Stock (TVTX)